RxDoctor Payments Data

Malika Coppedge, APRN

Nurse Practitioner · Las Vegas, NVNPI 1538557467

Payments from drug & device makers

$4,410in general payments, 2019–2025

Across 210 payments — averaging $21.00 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • Alkermes, Inc.$700
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$466
  • Johnson & Johnson$332
  • Otsuka America Pharmaceutical, Inc.$318
  • Neurocrine Biosciences, Inc.$299
  • plus $1K from 10 others

What the payments were for

  • Consulting fees$1153%
  • Travel & lodging$431%
  • Food & beverage$4,25396%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,410 in reported general payments places this provider in the 90th percentile of 933 nurse practitioner providers in Nevada.

See all nurse practitioner providers in Nevada

Medicare billing

Part B allowed, 2024
$13,702
Medicare patients
24
Services billed
153

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RexultiBrexpiprazole20$34,131
VraylarCariprazine Hcl12$17,028
Duloxetine Hcl30$1,013
Hydroxyzine Hcl31$833
Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine16$508
Buspirone Hcl39$488
Clonazepam57$410
Sertraline Hcl28$396
Trazodone Hcl46$368
Zolpidem Tartrate28$305
Quetiapine Fumarate28$283
Hydroxyzine Pamoate18$227
Alprazolam62$216
Temazepam15$205
Paroxetine Hcl30$197

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Otsuka America Pharmaceutical, Inc.Rexulti$318$34,13120 claims
AbbVieVraylar$1,169$17,02812 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 933 nurse practitioner providers in Nevada.

Other nurse practitioner in Las Vegas

See the full list for Nevada

Where these figures come from

Is this you, or does something look wrong? →